Hey, we all like free things from time to time. But for college students living on part-time wages and handouts from Mom and Dad, free is a way of life. The lure of free food brings many teenagers to events they wouldnt typically attend, and the endless supply of free T-shirts is half the fun of arriving at school during orientation week.
See Also: How to Cut Your Textbook Costs in Half Or More
Good news: The free or discounted services you can receive as a student dont end on campus. By showing your student ID or providing a university e-mail address, you can save money on everything from laptops to museum tickets.
And if youve graduated, dont assume that you cant still receive discounts. Taking even one course at a community college will grant you student status.
Top 5 Cheapest Companies To Own For 2017: Alexion Pharmaceuticals, Inc.(ALXN)
Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.
In the Company’s complement franchise, it offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. PNH and aHUS are severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in several therapeutic areas, including hematology, nephrology, transplant rejection and neurology. Soliris is a humanized monoclonal antibody that blocks terminal complement activity.
The Company has completed enrollment of patients in a Phase III multinational, placebo-controlled registration trial of eculizumab in patients with refractory generalized Myasthenia Gravis (MG). The Company is enrolling patients in a global, randomized, double-blind, placebo-controlled to evaluate eculizumab as a treatment for patients with relapsing neuromyelitis optica spectrum disorder (NMOSD). The Company has completed enrollment in a single, multinational, placebo-controlled delayed kidney transplant graft function (DGF) registration trial. The Company has completed a randomized, open-label, multicenter Phase II clinical tri! al of eculizumab presensitized kidney transplant patients at an elevated risk of antibody mediated rejection (AMR) receiving kidneys from living donors.
Strensiq (asfotase alfa)
In the Company’s metabolic franchise, it markets Strensiq for the treatment of patients with Hypophosphatasia (HPP). HPP is a genetic ultra-rare disease characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities. Strensiq is a targeted enzyme replacement therapy. It is designed to address underlying causes of HPP by aiming to restore the genetically defective metabolic process, thereby preventing or reversing the severe and potentially life-threatening complications in patients with HPP.
Kanuma (sebelipase alfa)
The Company offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). Kanuma is a recombinant form of the human LAL enzyme. It is an enzyme-replacement therapy, which is approved for the treatment for patients with LAL-D.
cPMP (ALXN 1101)
The Company has completed evaluation of its synthetic form of cyclic Pyranopterin Monophosphate (cPMP) replacement therapy in a Phase I healthy volunteer study. The Company has completed enrollment in a multi-center, multinational open-label clinical trial of synthetic cPMP in patients with Molybdenum Cofactor Deficiency (MoCD) Type A switched from treatment with recombinant cPMP. The Company has commenced the Phase II/III pivotal open-label, single-arm trial of ALXN1101 for treatment-naive neonates with MoCD Type A.
The Company’s product candidate, ALXN 1007, is a humanized antibody designed to target rare and severe inflammatory disorders and is a product of its antibody discovery technologies. The Company has completed enrollment in both a Phase I single-dose, dose escalating safety and pharmacology study in healthy voluntee rs, as well as in a multi-dose, dose escalating safety and p! harmacolo! gy study in healthy volunteers. The Company is conducting a proof-of-concept study in patients with an ultra-rare disorder, gastrointestinal graft versus host disease (GI-GVHD). The Company is conducting Phase II proof-of-concept study in patients with non-criteria manifestations of anti-phospholipid syndrome (APS).
The Company’s product candidate, SBC-103, is a recombinant form of natural human alpha-N-acetyl-glucosaminidase (NAGLU) enzyme, which leads to a buildup of abnormal amounts of heparan sulfate (HS) in the brain and throughout the body. SBC-103 is designed to replace the missing (or deficient) NAGLU enzyme.
The Company’s product candidate, ALXN 1210, is a next-generation complement inhibitor in development for PNH and other indications. The Company is conducting a multiple-ascending dose study of ALXN 1210 to evaluate the safety and efficacy of ALXN 1210. In addition, it has over two clinical stu dies of ALXN 1210 in patients with PNH. The Company also has initiated an open-label, multi-dose Phase II study of ALXN 1210 in patients with PNH that is designed to measure change in lactate dehydrogenase (LDH) levels and safety in several dosing cohorts and intervals.
- [By Ben Levisohn]
As biotech stocks like Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) get ready to report earnings, Piper Jaffray’s Joshua Schimmer and team write that they “would not be surprised to see the volatility continue.” They explain why:
Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…
We’ve been tracking the difference in PEG ratios between the biotech growth companies versus non-biotech growth companies (defined as market cap >$5B, EPS CAGR >20% by consensus, EPS >$1.00). The average biotech growth 2017E PEG ratio is now 0.4 points below that of non-biotech growth. Historically, when this spread widens, the biotech sector tends to outperform. We do note that in the past biotech has reached PEG ratio levels 0.5-0.7 below that of non-biotech growth alternatives, and we are seeing downward estimate revisions for many biotech names. if these trends continue for the sector, the spread in PEG ratios may be overstated and the sector could continue to languish. However, we are optimistic that bottom lines (if not top lines) will meet or exceed expectations as we head into 2Q earnings.
2Q outlook stronger for bottom lines than top lines, we believe: The outlook for 2Q is difficult to predict based on our recent IMS scrip ana
- [By Ben Levisohn]
Long-Term BucketBuy and hold; we consider these to be high-quality names that we see outperforming the group both in the current market and longer term: Celgene (CELG), Alexion Pharmaceuticals (ALXN), Jazz Pharmaceuticals (JAZZ).
- [By Ben Levisohn]
With biotech stocks like Alexion Pharmaceuticals (ALXN), Biogen (BIIB), Amgen (AMGN), Celgene (CELG) and Gilead Sciences (GILD) getting pounded following Britain’s decision to embrace the Brexit, Piper Jaffray’s Joshua Schimmer and team assess the damage:
Amid the broader sell-off, we continue to assess the impact of Brexit on our coverage universe. Overall, the direct UK impact on our large-cap coverage appears minimal on each company’s operations, though the broader volatility continues to weigh on the sector.Alexion Pharmaceuticals remains a top large-cap pick at these levels and view the recent sell-off and today’s ~9% move as an overreaction and would take advantage of the weakness. That said, we are entering unknown territory and it’s not certain if Britain becomes isolated and the EU ultimately unites around this (which is what we suspect will happen), or whether this is just the first in a series of dominoes that fragments the EU….
No immediate impact on operations: Immediate operations are not expected to be affected as the UK is not leaving immediately. Longer term is anyone’s guess, though we note that all the EU countries have always controlled their own reimbursement process, which is often a gating step in the process. That said, if the UK’s economy is negatively impacted this may negatively impact UK reimbursement decisions. Some companies likeGilead Sciences noted that the UK could be treated as non-EU countries, such as Switzerland and Turkey which would not be a major change…
Currency probably the biggest impact: While UK sales are generally minimal for individual companies, broader European exposure varies widely for each of our large-cap companies, withCelgene andAlexion Pharmaceuticals seeing the highest exposure followed by Amgen, Gilead Sciences, Incyte (INCY) and BioMarin Pharmaceutical (BMRN), andBiogen least so.
Shares of Alexi
Top 5 Cheapest Companies To Own For 2017: Occidental Petroleum Corporation(OXY)
Occidental Petroleum Corporation engages in the acquisition, exploration, and development of oil and gas properties in the United States and internationally. The company operates in three segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops, and produces oil and condensate, natural gas liquids (NGLs), and natural gas. The Chemical segment manufactures and markets basic chemicals, including chlorine, caustic soda, chlorinated organics, potassium chemicals, ethylene dichloride, chlorinated isocyanurates, sodium silicates, and calcium chloride; vinyls comprising vinyl chloride monomer and polyvinyl chloride; and other chemicals, such as resorcinol. The Midstream and Marketing segment gathers, processes, transports, stores, purchases, and markets oil, condensate, NGLs, natural gas, carbon dioxide, and power. This segment also trades around its assets consisting of transportat ion and storage capacity, as well as oil, NGLs, gas, and other commodities. Occidental Petroleum Corporation was founded in 1920 and is headquartered in Houston, Texas.
- [By Michael Flannelly]
Early on Monday, analysts at Deutsche Bank lowered their price target on Occidental Petroleum Corporation (OXY) to reflect a lower-than-expected valuation of an asset that the oil and gas exploration company is trying to sell.
Though the analysts lowered OXY’s price target from $114 to $109, they still maintain a “Buy” rating on the stock. The new price target suggests a 22% upside to the stock’s Friday closing price of $89.49.
Deutsche Bank analyst Paul Sankey said, “Bloomberg Finance LP reports that Oxy is seeking sale of 40% of Mideast operations for around $8bn, which would imply $20bn total value for the unit. However reportedly some suitors are valuing the asset at around $15bn. This is a relatively negative valuation against our previous view that Oxy would be seeking $25+bn for its MENA business. We are cutting our price target to $109/share to reflect this lower implied valuation.”
Occidental Petroleum shares were up 96 cents, or 1.07%, during pre-market trading on Monday. The stock is up 16.81% year-to-date.
- [By Ben Levisohn]
Stocks that made the cut include General Motors (GM), Coca-Cola Company (KO), Occidental Petroleum (OXY), JPMorgan Chase (JPM), and General Electric (GE).
- [By Ben Levisohn]
We have seen several dividend cuts in the recent past, including Anadarko Petroleum cutting its dividend by 81%…and we expect more companies to follow suit. Chesapeake Energy (CHK), ConocoPhillips (COP), Encana,Marathon Oil and Noble Energy (NBL) are among energy companies that have also cut dividends in the past 12 months, but dividend requirements even after several cuts will consume ~26% of 2016 estimated cash flow at current dividend rates (15% excluding Occidental Petroleum (OXY)) for the large cap E&Ps we cover. We believe most of the companies with a dividend yield of more than 1.5% should consider cutting the dividend and find the following companies more likely than not to reduce dividends:Apache (2.5% yield),Devon Energy (4%),Encana (1.5%) andMarathon Oil (2.5%). We believe Canadian Natural Resource (CNQ) (3.0%) is likely to maintain its dividend while Occidental (4.5%) has the financial strength to maintain or even increase the divide nd…
- [By Garrett Cook]
Citi notes that presentations from producers (the bank specifically notes Anadarko (NYSE: APC), Occidental Petroleum (NYSE: OXY), and Pioneer Natural Resources (NYSE: PXD)) showed a lack of commitment to enter 2017 hedge programs to lock in the economics for drilling.
10 Best Defense Stocks To Watch Right Now: PulteGroup, Inc.(PHM)
PulteGroup, Inc., through its subsidiaries, engages primarily in the homebuilding business in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on land. It offers various home designs, including single-family detached houses, townhouses, condominiums, and duplexes under the Pulte Homes, Del Webb, Centex, DiVosta Homes, John Wieland Homes, and Neighborhoods brand names. As of December 31, 2015, the company controlled 138,079 lots, which included 95,919 company owned lots and 42,160 lots under land option agreements. It also arranges financing through the origination of mortgage loans, principally for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. The company was formerly known as Pulte Homes, Inc. and changed its name to PulteGroup, Inc. in March 2010. PulteGroup, Inc. was founded in 1950 and is headquartered in Atlanta, Georgia.
- [By Eileen Rojas]
PulteGroup has high growth expectations
PulteGroup (NYSE: PHM ) reported $36 million, or $0.09 per share, of net income for its second quarter ended June 30. Net income included charges for several events that took place in the quarter. In the prior year’s quarter, the company reported net income of $42 million, or $0.11 per share. CEO Richard J. Dugas Jr. believes the housing market is on track to a long-term recovery. He finds that consumers see good value in the market, despite a limited supply of housing inventory, rising prices, and higher interest rates.
- [By Morgan Housel]
2. Homebuilders adding to supply. Homebuilders recently discovered something that’s been elusive for years: the ability to raise prices. The balance they now need to strike is how much to ramp up supply versus holding back supply to maximize prices. PulteGroup (NYSE: PHM ) CEO Richard Dugas said earlier this year: “In a number of communities across the country, demand has been so strong that we have taken action to slow the overall pace of sales.”
- [By Ben Levisohn]
KB Home (KBH) doesn’t report earnings until after the close, but the market isn’t taking any chances. Its shares–as well as those of homebuilders like PulteGroup (PHM) and DR Horton (DHI)–are getting whacked today following disappointing housing-starts data, and Lennar’s (LEN) below-consensus order growth.
Top 5 Cheapest Companies To Own For 2017: Terex Corporation(TEX)
Terex Corporation operates as a lifting and material handling solutions company. Its Aerial Work Platforms segment designs, manufactures, services, and markets aerial work platform equipment, telehandlers, and light towers, as well as related components and replacement parts under Terex and Genie names. The companys Construction segment offers compact construction equipment, including loader backhoes, mini and midi excavators, wheeled excavators, site dumpers, compaction rollers, skid steer loaders, and wheel loaders; and specialty equipment, such as material handlers, concrete mixer trucks, and concrete pavers. Its Cranes segment designs, manufactures, services, refurbishes, and markets mobile telescopic, tower, lattice boom crawler, lattice boom truck, utility equipment, and truck-mounted cranes, as well as related components and replacement parts under Terex name. The companys Material Handling & Port Solutions segment offers industrial cranes, such as universal cranes, process cranes, rope and chain hoists, electric motors, light crane systems, and crane components; and port and rail equipment, including mobile harbor cranes, straddle and sprinter carriers, gantry cranes, reach stackers, empty and full container handlers, general cargo lift trucks, automated stacking cranes, automated guided vehicles, terminal automation software, and related components and replacement parts. Its Materials Processing segment provides materials processing equipment, such as crushers, washing systems, screens, apron feeders, chippers, and related components and replacement parts under the Terex and Powerscreen brands. The company also provides financing solutions to assist customers in the rental, leasing, and acquisition of its products. It serves the construction, infrastructure, quarrying, mining, manufacturing, transportation, energy, and utility industries worldwide. Terex Corporation was founded in 19 25 and is based in Westport, Connecticut.
- [By Ben Levisohn]
Shares of Terex (TEX) had surged 32% as of the close of trading last Thursday–but dropped 14% the next day after China’s Zoomlion announced that it wouldn’t be pursuing a purchase of the U.S. crane maker after all. In the aftermath of the scuttled deal, Morgan Stanley’s Mili Pothiwala and Nigel Coe cut Terex to Equal Weight from Overweight:
Balint Porneczi/Bloomberg News
On Friday morning, Zoomlion announced it had terminated its bid for its proposed acquisition of Terex for $31/ share. This was a clear negative for Terex shares, which traded down ~15% on Friday to $20, given the absence of an event-driven catalyst (following the sale of MHPS to Konecranes, which we assume will be completed). However, we think that the stock’s current discount to the Machinery group on a P/E basis (20%+) is justified, given a still challenged underlying operating environment for the RemainCo, as well as historically uneven company execution – both of which return to the forefront of the investment debate following the removal of the M&A bull case.
To which all we can say is: Oops.
Shares of Terex have dropped 0.5% to $20.78
- [By Ben Levisohn]
Third and a trigger for the change: China becomes an active bidder in the space. Chinas Zoomlion bid for Terex (TEX) ($3.3B) along with Haier/General Electric (GE) ($5.4B) and several ChemChina proposed deals in industrials changes the upside/downside skew, particularly on lower quality/more challenged names. The Terex bid does not appear to be one-off. Chinese outbound M&A announcements rose to record highs in 15; to $112B (up 57% from 2014) in total acquisitions. Industrials formed a large and rising portion, at ~12B completed. Thats roughly equal to the 3 prior years industrials deals combined, and is the highest on record. Energy and materials accounted for ~15% of 15 spend vs. ~83% in 2011. Even lower quality or more currently challenged machinery franchises have distribution which could be highly attractive to new entrants…
- [By Ben Levisohn]
Yesterday, Terex (TEX) announced that it would sell its ports business to Konecranes for $1.3 billion. Today, Baird’s Mircea Dobre and Joseph Grabowski upgraded Terex to Outperform from Neutral, arguing that the sale makes a takeover by China’s Zoomlion that much easier. They explain:
Balint Porneczi/Bloomberg News
The sale of MHPS to Konecranes is a positive catalyst on multiple fronts: shareholders got an attractive multiple for what historically has been a challenged business with further upside possible given 25% equity ownership in Konecranes, execution risk is diminished as new CEO can focus on operational improvement without the effort required to integrate the Terex and Konecranes businesses, and finally, the MHPS sale makes it easier for Zoomlion to acquire remaining Terex.
While our upgrade is not reliant on Zoomlion acquiring Terex, the MHPS transaction could make a firm Zoomlion offer more likely.
At the margin, a Zoomlion deal appears easier to get done: 1) the remaining businesses fit better with Zoomlions existing product portfolio of construction equipment, cranes, and various commercial and municipal equipment, 2) given the attractive terms of the MHPS sale, the funding hurdle required to acquire Terex is lowered, 3) many of the CFIUS issues center around national security concerns regarding the nations ports, no longer a concern given MHPS sale.
Dobre and Grabowski also raised their price target on Terex to $30, up from $24. With Terex off 0.1% at $24.88 today, that leaves 21% upside in the stock to Baird’s target.
In February, I wrote about Chinese demand for U.S. companies, including Terex.
Top 5 Cheapest Companies To Own For 2017: Immunomedics, Inc.(IMMU)
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer. It is also developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II trials for the treatment of metastatic colorectal cancer; and epratuzumab, which is in two Phase III clinical trials for the treatment of systemic lupus erythematosus. Its early-stage products include Veltuzumab, a humanized monoclonal antibody targeting CD20 r eceptors on B lymphocytes for the treatment of non-Hodgkin lymphoma (NHL) and autoimmune diseases; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is in Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product candidate for patients with NHL or acute lymphoblastic leukemia; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headqua rtered in Morris Plains, New Jersey.
- [By Monica Gerson]
Immunomedics, Inc. (NASDAQ: IMMU) fell 3.38 percent to $4.00 in pre-market trading after dropping 0.72 percent on Friday.
ViaSat, Inc. (NASDAQ: VSAT) shares fell 1.53 percent to $72.87. Drexel Hamilton downgraded Viasat from Hold to Sell.
- [By Lisa Levin]
Immunomedics, Inc. (NASDAQ: IMMU) shares dropped 18 percent to $4.32 as the company issued an update on triple-negative breast cancer presentation at the the American Society of Clinical Oncology. Immunomedics said that triple-negative breast cancer presentation was cancelled following a complaint that the company violated the embargo.